Table of Contents List of Tables List of Figures Introduction Global Markets Direct Report Coverage Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) - Overview Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) - Therapeutics Development Products under Development by Stage of Development Products under Development by Therapy Area Products under Development by Indication Products under Development by Companies Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) - Therapeutics Assessment Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) - Companies Involved in Therapeutics Development Bavarian Nordic A/S MedImmune LLC Visterra Inc Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) - Drug Profiles Monoclonal Antibodies to Inhibit RSV-G and F Proteins for RSV Infections - Drug Profile Product Description Mechanism Of Action R&D Progress MVA-RSV - Drug Profile Product Description Mechanism Of Action R&D Progress respiratory syncytial virus (virus like particle) vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress respiratory syncytial virus vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress respiratory syncytial virus vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress TRL-3D3 - Drug Profile Product Description Mechanism Of Action R&D Progress VIS-RSV - Drug Profile Product Description Mechanism Of Action R&D Progress Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) - Dormant Products Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) - Product Development Milestones Featured News & Press Releases Aug 08, 2018: Bavarian Nordic Announces Positive Data from Phase 2 Extension Study of its Universal RSV Vaccine Mar 06, 2018: Bavarian Nordic Announces Additional Positive Data from a Phase 2 Study of its Universal RSV Vaccine Nov 09, 2017: Bavarian Nordic Announces Initiation of Phase 2 Booster Study of its Universal RSV Vaccine Sep 21, 2017: Bavarian Nordic Provides Update on its Universal RSV Vaccine Jun 27, 2017: Bavarian Nordic Announces Positive Data from Ongoing Phase 2 Study Investigating a Universal RSV Vaccine Feb 23, 2017: Updated Phase 1 Data Show Bavarian Nordic's Vaccine Candidate Induces a Broad and Durable Immune Response against RSV Dec 14, 2016: Bavarian Nordic Announces Completion of Enrollment for Phase 2 Clinical Trial of RSV Vaccine Oct 18, 2016: Bavarian Nordic Announces Initiation of Phase 2 Clinical Trial of RSV Vaccine Sep 29, 2016: Bavarian Nordic Announces Presentation Of Phase 1 Data For Its RSV Vaccine At International RSV Symposium May 23, 2016: Bavarian Nordic Announces Positive Top Line Results from a Phase 1 Trial of a Novel, Broad Spectrum RSV Vaccine in Healthy Adult and Elderly Populations Aug 18, 2015: Bavarian Nordic Initiates Phase 1 Clinical Trial of MVA-BN in Respiratory Syncitial Virus Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer

List of Tables Number of Products under Development by Stage of Development, H1 2019 Number of Products under Development by Therapy Areas, H1 2019 Number of Products under Development by Indication, H1 2019 Number of Products under Development by Companies, H1 2019 Products under Development by Companies, H1 2019 Number of Products by Stage and Mechanism of Actions, H1 2019 Number of Products by Stage and Route of Administration, H1 2019 Number of Products by Stage and Molecule Type, H1 2019 Pipeline by Bavarian Nordic A/S, H1 2019 Pipeline by MedImmune LLC, H1 2019 Pipeline by Visterra Inc, H1 2019 Dormant Projects, H1 2019List of Figures Number of Products under Development by Stage of Development, H1 2019 Number of Products by Stage and Mechanism of Actions, H1 2019 Number of Products by Routes of Administration, H1 2019 Number of Products by Stage and Routes of Administration, H1 2019 Number of Products by Molecule Types, H1 2019 Number of Products by Stage and Molecule Types, H1 2019

Bavarian Nordic A/S MedImmune LLC Visterra Inc